CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPANTS

• 收藏
• 分享

专利权人:

BIOGEN INC.

发明人:

ANTONIO J. GRILLO-LOPEZ,JOHN E. LEONARD

申请号：

MYPI 99004860

公开号：

MY155913A

申请日:

1999.11.09

申请国别(地区):

MY

年份:

2015

代理人:

摘要：

THE USE OF A CHIMERIC ANTI-CD20 ANTIBODY, RITUXAN®, AS AN IN VIVO OR IN VITRO PURGING AGENT, OF PATIENTS RECEIVING BONE MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANT DURING TREATMENT OF B-CELL-RELATED MALIGNANCIES, E.G., B-CELL LYMPHOMAS OR LEUKEMIAS, IS DISCLOSED. SUCH PURGING MAY ENHANCE ENGRAFTMENT AND/OR PREVENT DISEASE RELAPSE IN SUCH PATIENTS.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/